Drug Profile

Insulin 147 and PCSK9 inibitor - Novo Nordisk

Alternative Names: Insulin and PCSK9i hybrid; Insulin-147

Latest Information Update: 16 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novo Nordisk
Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
Mechanism of Action Ornithine decarboxylase stimulants; PCSK9 protein inhibitors; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

16 Feb 2022 Discontinued - Phase-I for Diabetes mellitus in Denmark, as of February 2022 (SC) (Novo Nordisk pipeline, February 2022)
24 Nov 2021 Insulin 147 is available for licensing as of 17 Nov 2021. https://www.novonordisk.com/partnering-and-open-innovation/contact-us-about-partnering.html
31 Jan 2020 Phase-I clinical trials in Diabetes mellitus in Denmark (SC)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com